Bronchogen
Khavinson lung peptide bioregulator
Bronchogen (Khavinson lung peptide bioregulator) is a longevity & bioregulators research compound. Short peptide bioregulator targeting bronchopulmonary tissue — proposed to support respiratory-tissue gene expression.
Bronchogen quick facts
| Reported research dose | .5-2mg |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | Short |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Respiratory-tissue bioregulator, run as a short course. Niche. Airway-directed and genuinely niche — worth it if you have a specific respiratory reason, not as a general longevity add. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, a peak-flow meter costs very little and gives you a real number. Run it as an experiment you measure, not a protocol you trust.
How Bronchogen works
Short peptide bioregulator targeting bronchopulmonary tissue — proposed to support respiratory-tissue gene expression.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Bronchogen
Buy Bronchogen at Ion Peptide →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Bronchogen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for respiratory tissue support, typically in oral courses and often paired with Chonluten or Taxorest. Interest rose considerably after 2020 for obvious reasons, without any evidence arriving to match it.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- Ala-Glu-Asp-Leu — a defined tetrapeptide targeting bronchopulmonary tissue.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- Lung is a plausible target and a hard one to read. Respiratory function is measurable with cheap spirometry, so a controlled test would be straightforward — the absence of one after decades of sale is the relevant fact.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Bronchogen actually does
Bronchogen is four amino acids long, and the first thing to know about it is that the published record does not agree on their order. This site's catalog and the originating group's own 2021 gene-expression review write it Ala-Glu-Asp-Leu. The single primary paper published under the trade name writes it Ala-Asp-Glu-Leu, in its own title Monaselidze 2011. Those two are positional isomers: same composition, C18H30N4O9, same average mass, 446.47 Da. No mass spectrometer separates them. A certificate of analysis reporting 446.5 Da is equally consistent with either molecule, which makes the mass number on a vendor's paperwork weaker evidence than it looks.
The chemistry that follows is the same either way. Glutamate and aspartate each carry a side-chain carboxyl; add the C-terminal carboxyl, subtract the protonated N-terminal amine, and the computed net charge at blood pH is about −2.06, with an isoelectric point of 3.55. At the pH of plasma this molecule is a dianion, and a 446 Da dianion does not cross a lipid membrane by diffusion in either direction. It needs a transporter, or it stays where you put it.
Here is where the mechanism gets specific, and where it gets thin. The carriers this school proposes are the proton-coupled oligopeptide transporters PEPT1 and PEPT2 and the L-type amino acid transporters LAT1 and LAT2 Khavinson 2022. The substrate range they describe for those carriers is di- and tripeptides — 2 and 3 residues. Bronchogen has 4. The 2023 follow-up that scored 26 of these peptides against LAT1, LAT2 and PEPT1 did it by molecular docking, compared against all 8,400 possible di- and tripeptides, and measured no transport in any living cell Khavinson 2023. So the delivery half of this compound's story is a binding energy, not a flux.
And the DNA half has a result nobody quotes. Microcalorimetry found that bronchogen raised the melting temperature of DNA by 3.1°C — that is real binding and it is easy to measure — but the DNA came from calf thymus and mouse liver, and the authors read the interaction as running to the nitrogen bases of both strands rather than to particular base pairs Monaselidze 2011. Non-specific stabilization is the opposite of promoter recognition. A molecule that stiffens whatever DNA it meets is not a molecule reading a lung gene, and the tissue-specificity claim has to come from somewhere other than this experiment.
Cell, rodent, human — and where it stops
Step one, in a tube, with no cells in it. Calf thymus and mouse liver DNA, differential scanning microcalorimetry, melting temperature up 3.1°C, binding described as non-specific Monaselidze 2011. Note the tissue those two DNA samples came from: thymus and liver. Neither is lung. Nothing in this experiment distinguishes a bronchial promoter from any other stretch of double-stranded DNA, and the systematic search for peptide-DNA structural motifs that this group later published sets out how much harder sequence-specific recognition is than generic binding Kolchina 2019.
Step two, in cell culture. The 2021 gene-expression review credits AEDL with stimulating differentiation of lung cells and with regulating the functional activity of bronchial epithelium, naming NKX2-1, SCGB1A1, SCGB3A2, FOXA1 and FOXA2 among the genes, and the mucins MUC4 and MUC5AC and the surfactant gene SFTPA1 in bronchial epithelium Khavinson 2021. The same review reports AEDL among the peptides binding fluorescently tagged histones H1, H2B, H3 and H4. Cultured cells, in every case, with the peptide added to the medium — which is a route no person has. And the step everything above depends on, a short peptide actually crossing into the nucleus, was demonstrated in HeLa cells Fedoreyeva 2011 — a cervical carcinoma line, not airway epithelium and not any tissue this product names. There is one older step worth adding: organotypic culture of lung explants from 3-week-old and 18-month-old rats, with bronchogen applied at 0.05 ng/mL alongside cardiogen, prostamax and pancragen on their own tissues, reported a stimulating effect against control explants in all groups Zakutskiĭ 2006. Note what that abstract does not say: whether any peptide was ever put on a non-matching tissue. The cross arm is what would make the word 'tissue-specific' in its own title into a result.
Step three, in rodents, and this is the strongest link in the chain. Rats, chronic obstructive pulmonary disease modeled by 60 days of intermittent nitrogen dioxide exposure, then the tetrapeptide for 1 month Kuzubova 2015. What was measured was histology and lavage, not symptoms: goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema were reported eliminated, ciliated cells restored, secretory IgA production increased, and the cell composition and proinflammatory cytokine profile of the bronchoalveolar space normalized. That is a coherent set of readouts pointing one way, and it is the reason this compound deserves a serious page rather than a dismissive one.
Step four, in humans: zero. No randomized trial, no controlled trial, no published case series with a spirometry endpoint. The independent systematic review of this general family pooled 24 randomized trials over 2,245 participants and found none of them here — it covered cognitive endpoints, rated risk of bias moderate to high and certainty of evidence low to very low, and contains no respiratory arm at all Alsulaimani 2021.
The obstacles, named one at a time. (1) The rat abstract does not state the route, so the single best animal result cannot be compared to what a person does with a vial. (2) A 60-day nitrogen dioxide exposure in a young rat is chemical injury, not 30 years of cigarettes plus a genotype; the lesion is reversible in ways human emphysema is not. (3) The carrier argument runs against this molecule rather than for it, because 4 residues sit outside the 2-to-3 range the group's own transport work describes, and the 2023 assessment was docking rather than uptake Khavinson 2023. (4) Every gene-level result is in culture. (5) The sequence itself is unsettled between the primary paper and the review, so it is not certain that the rat study and the culture work were even done on the same molecule.
Bronchogen pharmacokinetics — how much of it actually gets in
The catalog says ‘Short’. That is true and it is not an answer, so here is the arithmetic the blank was standing in for.
What destroys it. A free N-terminal alanine is a substrate for aminopeptidase N, which sits on endothelium and on the intestinal brush border; dipeptidyl peptidases take pairs off the same end. There is no ring, no D-amino acid, no N-acetyl cap and no C-terminal amide on this molecule to slow any of that down, which is exactly why the unmodified acid form computes to a net charge of −2.06 rather than the −1.06 an amidated version would carry. Nothing has been measured: 0 published pharmacokinetic studies in any species, in any language, for this compound.
The oral barrier, which is the one that matters for the capsule form. A swallowed tetrapeptide meets gastric acid, pancreatic proteases and then the brush-border peptidases before it reaches an enterocyte, and the named route across that cell layer is PEPT1, whose described substrate range is di- and tripeptides Khavinson 2022. Anything that did cross would then face hepatic first-pass extraction before reaching an artery. No oral bioavailability figure exists for this molecule or for any compound in this family. So bound it instead of guessing at it: if the surviving fraction were as generous as 1 in 10, an oral course and a subcutaneous course would still differ about 10x in delivered material, and no published measurement exists that could tell a 10x gap from a 1,000x one. The fraction is unmeasured and the mechanism gives no reason to expect it to be large.
The injectable comparator, and why it does not settle it either. Subcutaneous injection bypasses the gut and the liver entirely, so it removes both barriers above — and then hands the molecule to plasma aminopeptidases with nothing to protect it. For a small unmodified anionic peptide the expected plasma residence is minutes rather than hours, which is why the courses in this class are daily. That is a mechanistic expectation and not a measurement, and it is worth saying which is which: 100% of the pharmacokinetic statements on this page, including the ones that sound confident, are inferences from chemistry.
What would have to be true, and how you would know it was not
Three predictions, and the third is the one that argues against buying this.
1. Secretory IgA is the marker their own rat study moved, and nobody has ever measured it in a person taking this. Salivary or sputum secretory IgA is a cheap, non-invasive assay. If the rat result transfers, it should rise over a 30 to 42-day course. If it does not move, the best animal finding in this compound's file did not carry into a human, and that is worth knowing whichever way it lands.
2. hs-CRP should not move, and if it falls that is probably the season rather than the peptide. The rat mechanism is epithelial remodeling and local cytokine normalization, not systemic anti-inflammation, so a whole-body inflammation marker is the wrong place to look for a true positive and the right place to catch a false one. Draw hs-CRP and a CBC with differential at baseline and again at 3 months, which is this site's own retest window for hs-CRP, and read the eosinophil count on the CBC as the allergic-airway confounder it is. TNF-alpha, retested at 3 months, is the closest circulating analog to what was measured in the rats' lavage fluid, and it is measured in blood rather than in the airway, which is precisely the gap.
3. The prediction that cuts the other way: sputum could increase before it decreases. The gene list credited to this peptide in bronchial epithelium includes MUC4 and MUC5AC, the airway mucins Khavinson 2021, and the direction of that regulation is not published. In a rat with induced obstruction the reported outcome was less goblet-cell hyperplasia, which is the opposite of more mucus. Both cannot be the general case. Anyone running this in chronic bronchitis should log daily sputum volume and color for the whole course, because a rise is a plausible mechanistic outcome, it is the cheapest observation available, and no published data can tell you which way it will go.
What nobody has tested yet
Four experiments nobody has run, each one cheap enough that the reason it has not been done is that nobody asked.
1. Nobody has sequenced a vial. The isomer problem at the top of this page is settled by tandem mass spectrometry or Edman degradation in an afternoon and by nothing else — mass alone cannot do it, because Ala-Glu-Asp-Leu and Ala-Asp-Glu-Leu both weigh 446.47 Da. Ask a vendor for the MS/MS fragmentation, not the mass. As far as any public record shows, 0 vendors in this market publish it.
2. Nobody has put it on a Caco-2 monolayer. That is the standard intestinal-absorption assay, it reports an apparent permeability coefficient in cm/s, it takes about 3 weeks including monolayer differentiation, and it would convert the entire oral delivery argument from a docking score into a number. PEPT1 is expressed in that model, so the experiment tests the exact claim being made Khavinson 2023.
3. Nobody has repeated the DNA melting experiment against a lung promoter. The 3.1°C shift was measured on calf thymus and mouse liver DNA Monaselidze 2011. Run the same microcalorimetry against a defined NKX2-1 or SCGB1A1 promoter oligonucleotide beside a scrambled control of identical base composition, and the tissue-specificity claim either survives or collapses. It is a week of work on equipment that already exists, and in 15 years since the original nobody has published it.
4. No human respiratory endpoint of any kind has been collected. Not a peak flow diary, not spirometry, not exhaled nitric oxide, not a 6-minute walk. Home peak-flow meters cost less than a course. A group of 20 people logging morning peak flow through a 42-day course and 42 days after would produce the first human respiratory dataset that exists for this molecule.
Bronchogen — its own safety story, not its class's
The class block on this page is written for injectable peptides in general. Two things about this one are not general.
The real risk is diagnostic delay, and the airway is a bad place to accept it. Coughing up blood, unintended weight loss, a cough that has changed in a smoker, new breathlessness on flat ground, or a hoarse voice lasting more than 3 weeks are red flags for lung cancer and for several other things, and none of them are reasons to run a peptide course. Spirometry costs little, is available in most primary care, and gives a number this compound has never been tested against. A person self-treating a symptom is postponing the test that would name it.
The mechanism-specific unknown is the mucin arm. If the regulation of MUC4 and MUC5AC credited to this peptide in cultured bronchial epithelium runs upward Khavinson 2021, the population most likely to buy it — people with chronic productive cough — is the population in which more mucin expression is least welcome. Nobody has published the direction. That is a genuine open risk rather than a formality, and it is invisible on a vendor page.
What the absence of reported harm is worth. There are 0 published adverse events for this compound, and that number reflects the absence of a reporting system rather than the presence of safety: with 0 human trials there is no arm in which an event could have been recorded. Sterile technique and a clean injection site are the concrete risks here, and they belong to the needle rather than to the molecule.
Sources read for this page
- Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology 2006 · PMID 17152728
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow) 2011;76(11):1210–1219 · PMID 22117547
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine 2011;150(3):375–377 · PMID 21240358
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bulletin of Experimental Biology and Medicine 2015;159(5):685–688 · PMID 26468022
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
Bronchogen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Bronchogen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Bronchogen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Bronchogen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Bronchogen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Bronchogen — frequently asked questions
What is Bronchogen?
Bronchogen (Khavinson lung peptide bioregulator) is a longevity & bioregulators research compound. Short peptide bioregulator targeting bronchopulmonary tissue — proposed to support respiratory-tissue gene expression.
Is the full Bronchogen protocol on this page?
The reported research dose is on this page, along with how Bronchogen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Bronchogen?
Bronchogen has an approximate half-life of Short, which is part of what determines how often it's dosed.
What's the evidence behind Bronchogen?
Current evidence level: Russian studies; limited. Bronchogen is offered for research purposes only and is not an approved medicine.
Bronchogen inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Bronchogen is used for
Bronchogen appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Bronchogen is the delivery arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.